Who owns ASCENDIS PHARMA A/S?
- CUSIP Number: 04351pad3
Tip: Access positions for across all investors
Analyze quarterly positions in Ascendis Pharma A/s with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Ascendis Pharma A/s stock
Who bought or sold ASCENDIS PHARMA A/S this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| Linden Advisors | 145M | $198M | -6% | Sep 2025 |
|
| Wolverine Asset Management | 93M | $127M | 2% | Sep 2025 |
|
| Franklin Resources | 47M | $65M | -1% | Sep 2025 |
|
| Lazard Asset Management | 35M | $480k | 2% | Sep 2025 |
|
| DeepCurrents Investment Group | 26M | $35M | 86% | Sep 2025 |
|
| Opti Capital Management | 21M | $29B | 100% | Sep 2025 |
|
| Point72 Asset Management | 20M | $27M | 0% | Sep 2025 |
|
| Davidson Kempner Capital Management | 18M | $25M | -23% | Sep 2025 |
|
| Capstone Investment Advisors | 18M | $24M | 129% | Sep 2025 |
|
| State Street Corporation | 12M | $17M | 13% | Sep 2025 |
|
| Partner Fund Management | 12M | $16M | -50% | Sep 2025 |
|
| SSI Investment Management | 9.8M | $13M | -19% | Sep 2025 |
|
| Nicholas Investments Partners | 6.0M | $8.2M | 41% | Sep 2025 |
|
| Morgan Stanley | 5.9M | $7.4M | 100% | Jun 2025 |
|
| BlackRock | 5.5M | $7.5M | -2% | Sep 2025 |
|
| Ameriprise Financial | 5.5M | $7.5M | 22% | Sep 2025 |
|
| Polar Capital Holdings | 5.0M | $6.8M | 100% | Sep 2025 |
|
| CSS | 4.4M | $6.0M | -16% | Sep 2025 |
|
| DAFNA Capital Management | 4.0M | $5.4M | 0% | Sep 2025 |
|
| Shenkman Capital Management | 3.1M | $4.4B | 10% | Sep 2025 |
|
| State of Wisconsin Investment Board | 3.0M | $4.1M | 50% | Sep 2025 |
|
| Bnp Paribas Investment Partners | 2.0M | $2.8M | 0% | Sep 2025 |
|
| Invesco | 2.0M | $2.7M | 0% | Sep 2025 |
|
| Man Group | 1.7M | $2.3M | 0% | Sep 2025 |
|
| Ing Investment Management | 1.7M | $2.3M | -5% | Sep 2025 |
|
| Millennium Management | 1.5M | $2.0M | 0% | Sep 2025 |
|
| RWC Asset Management | 1.5M | $2.0M | -1% | Sep 2025 |
|
| Leucadia National Corporation | 1.4M | $2.0M | -56% | Sep 2025 |
|
| Royal Bank of Canada | 1.2M | $1.6M | -36% | Sep 2025 |
|
| Zazove Associates | 1.1M | $1.4M | -86% | Sep 2025 |
|
| Oaktree Capital Management | 1.0M | $1.4M | -23% | Sep 2025 |
|
| Bnp Paribas Arbitrage, Snc | 997k | $1.4M | 35% | Sep 2025 |
|
| Union Bancaire Privee, UBP SA | 520k | $597k | 0% | Sep 2025 |
|
| Jpmorgan Chase & Co | 458k | $607k | 100% | Sep 2025 |
|
| Jane Street | 450k | $616k | 100% | Sep 2025 |
|
| Deutsche Bank Aktiengesellschaft | 375k | $510k | 0% | Sep 2025 |
|
| Central Pacific Bank - Trust Division | 344k | $468k | -29% | Sep 2025 |
|
| Bank of New York Mellon | 300k | $398k | 0% | Sep 2025 |
|
| Lombard Odier Asset Management | 212k | $47M | 100% | Sep 2025 |
|
| SG Americas Securities | 180k | $25M | 0% | Sep 2025 |
|
| Russell Investments | 180k | $248k | -52% | Sep 2025 |
|
Who sold out of Ascendis Pharma A/s?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Tenor Capital Management | Jun 2025 | 7.3M | $9.1M |
| Jump Financial | Jun 2025 | 4.0M | $5.0M |
| Wellesley Investment Advisors | Jun 2025 | 3.5M | $4.4B |
| KBC Group NV | Mar 2025 | 200k | $237k |